ARQT — Arcutis Biotherapeutics Inc
In 2026 Q2, 7 of the 140 tracked hedge funds reported a position in Arcutis Biotherapeutics Inc (ARQT), worth $179.70M combined. Over the quarter 4 opened or added, 3 trimmed or exited.
Hedge fund holders, 2026 Q2
| Fund | Value | Portfolio % | Change |
|---|---|---|---|
| Polar Capital | $173.23M | 0.49% | +16.6% |
| Essex | $3.61M | 0.47% | -4.5% |
| Renaissance | $1.53M | 0.00% | -86.8% |
| Navellier | $516.43K | 0.04% | +43.2% |
| Quadrature | $363.28K | 0.00% | -40.2% |
| Persistent | $226.99K | 0.07% | NEW |
| Caxton Associates | $219.57K | 0.00% | NEW |
All stocks · Quarterly Trends · Hedge Fund Tracker
Source: SEC EDGAR 13F filings, reported as of quarter end and filed up to 45 days later. Not investment advice.